Ryan Daly, MD
Cardiovascular Disease · Indianapolis, INNPI 1598937484
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $14,050 of the $18,657 with a category attached, or 75.3%. AstraZeneca accounts for 81.0% of it on its own, with 27 other manufacturers making up the rest. Reporting peaked in 2019 at $6,484 and has fallen 88.9% since, to $717 in 2025.
Across 186 payments — averaging $100.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$15K
- Novartis$483
- Johnson & Johnson$448
- E.r. Squibb & Sons, L.L.C.$405
- Heartflow, Inc.$301
- Amgen$282
- plus $2K from 22 others
Across 7 payments — averaging $7023.18 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Heartflow, Inc.$30K
- Cleerly, Inc.$19K
What the payments were for
- Speaking & faculty fees$14,05075%
- Travel & lodging$800%
- Food & beverage$4,50024%
- Education$270%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 36 | $15,117 |
| Novartis | 28 | $483 |
| Johnson & Johnson | 18 | $448 |
| E.r. Squibb & Sons, L.L.C. | 10 | $405 |
| Heartflow, Inc. | 5 | $301 |
| Amgen | 17 | $282 |
| Boston Scientific | 12 | $231 |
| Siemens Medical Solutions USA, Inc. | 2 | $228 |
| Pfizer | 12 | $192 |
| Merck | 9 | $153 |
| Cleerly, Inc. | 1 | $129 |
| Novo Nordisk | 6 | $122 |
| Boehringer Ingelheim | 6 | $100 |
| GE HealthCare | 1 | $79 |
| Bayer | 4 | $62 |
| Kestra Medical Technology Services, Inc. | 2 | $45 |
| Amarin Pharma, Inc. | 3 | $44 |
| Philips North America LLC | 1 | $38 |
| Abbott | 2 | $34 |
| Lexicon Pharmaceuticals, Inc. | 2 | $31 |
| Terumo Medical Corporation | 1 | $26 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $19 |
| Lilly USA, LLC | 1 | $17 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $16 |
| Esperion Therapeutics, Inc. | 1 | $15 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $14 |
| UCB, Inc. | 1 | $13 |
| Lantheus Medical Imaging, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$14,671
- FFRct$252
- NAEOTOM Alpha$191
- Cleerly Ischemia$129
- Cleerly Labs$129
- XARELTO$125
- OPDIVO$125
- INVOKANA$102
How this compares
$18,657 in reported general payments places this provider in the 85th percentile of 408 cardiovascular disease providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 414 | $573,032 |
| JardianceEmpagliflozin | 199 | $256,169 |
| EntrestoSacubitril/Valsartan | 174 | $236,743 |
| Repatha SureclickEvolocumab | 99 | $100,936 |
| XareltoRivaroxaban | 68 | $86,871 |
| FarxigaDapagliflozin Propanediol | 67 | $70,104 |
| VascepaIcosapent Ethyl | 75 | $62,042 |
| MultaqDronedarone Hcl | 14 | $22,524 |
| BrilintaTicagrelor | 14 | $15,291 |
| OzempicSemaglutide | 12 | $12,957 |
| Ezetimibe | 477 | $9,982 |
| Atorvastatin Calcium | 883 | $7,672 |
| Metoprolol Succinate | 598 | $7,464 |
| Carvedilol | 697 | $5,363 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 12 | $5,111 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $192 | $573,032414 claims |
| Boehringer IngelheimJardiance | $100 | $256,169199 claims |
| NovartisEntresto | $483 | $236,743174 claims |
| Johnson & JohnsonXarelto | $448 | $86,87168 claims |
| AstraZenecaFarxiga, Brilinta | $15,117 | $85,39681 claims |
| Novo NordiskOzempic | $122 | $12,95712 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 408 cardiovascular disease providers in Indiana.
Other cardiovascular disease in Indianapolis
- John MillerIndianapolis$354K
- David KovacichIndianapolis$327K
- Vijay RaoIndianapolis$247K
- Atul ChughIndianapolis$242K
- James TrippiIndianapolis$239K
- Christopher HealyIndianapolis$209K
- Richard KovacsIndianapolis$136K
- George LolayIndianapolis$128K
- Onyedika IlonzeIndianapolis$125K
- Noel DasguptaIndianapolis$122K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.